New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2013
10:32 EDTPFE, MRKPfizer results may indicate weakness for Merck, says Wells Fargo
Wells Fargo notes that Pfizer's (PFE) Q1 revenue and earnings were impacted by weakness in the Japanese Yen. The firm says Merck (MRK) has growing exposure to the Japanese Yen, especially for the Januvia franchise. Japan represented 10.8% of Merck's 2012 revenue, but the company should be helped by its hedges, Wells added. The firm has an Outperform rating on shares of Merck.
News For MRK;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
September 28, 2015
15:18 EDTMRKMerck volatility at 52-week high
Subscribe for More Information
15:01 EDTPFEPfizer volatility at high end of one-year range
Subscribe for More Information
08:02 EDTMRKSyndax and Merck announce patients dosed in trial of Entinostat and Keytruda
Subscribe for More Information
07:52 EDTMRK, PFEIIR Holdings to hold a conference
Subscribe for More Information
07:31 EDTMRKMerck says Japan's PMDA approves Marizev DPP-4 inhibitor for Type 2 diabetes
Subscribe for More Information
07:27 EDTPFEFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information
September 27, 2015
16:47 EDTMRKMerck reports Phase 1b data on Keytruda for two gastrointestinal cancers
Subscribe for More Information
14:58 EDTMRKMerck announces Phase 1b data on Keytruda for nasopharyngeal cancer
Subscribe for More Information
September 25, 2015
16:00 EDTPFEOptions Update; September 25, 2015
iPath S&P 500 VIX Short-Term Futures up 66c to 25.09. Option volume leaders: AAPL NFLX BAC FB AU NKE PFE INTC AMZN TSLA
15:31 EDTMRKMerck volatility elevated as shares trend lower
Merck October weekly call option implied volatility is at 39, October is at 34, November is a 29; compared to its 52-week range of 15 to 34, suggesting large price movement after presidential candidate Hilary Clinton announced plans early this week to cap prescription drug prices.
09:34 EDTPFEActive equity options trading on open
Active equity options trading on open: AAPL BAC FB NKE NFLX PFE AU TSLA
08:15 EDTMRKMerck narrow Keytruda label may not matter as much as thought, says Bernstein
Subscribe for More Information
07:22 EDTPFEEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
07:03 EDTPFEMerck KGaA, Pfizer announce FDA orphan drug designation for avelumab
Subscribe for More Information
05:08 EDTPFEStocks with implied volatility movement; PFE HLF
Subscribe for More Information
September 24, 2015
17:04 EDTMRK, PFEMerck, Pfizer to collaborate with Agilent's Dako on Avelumab diagnostic
Subscribe for More Information
16:03 EDTMRKNewLink Genetics awarded $8.1M from DTRA to advance Ebola vaccine
NewLink Genetics (NLNK) announced that the Defense Threat Reduction Agency of the Department of Defense has awarded a subsidiary of NewLink Genetics an $8.1M base contract with future options totaling $5.2M to support various development activities of the investigational rVSV-ZEBOV Ebola) vaccine candidate. NewLink has exclusively licensed research, development and manufacturing of the rVSV-ZEBOV vaccine to Merck (MRK). In late 2014, Merck, known as MSD outside the United States and Canada, licensed the vaccine from NewLink Genetics to apply Merck's vaccine expertise to help accelerate the development of this vaccine candidate. Clinical studies of the rVSV-ZEBOV are ongoing.
07:33 EDTPFEBIND says Pfizer exercises option to obtain license for Accurin drug candidate
BIND Therapeutics (BIND) announced that Pfizer (PFE) exercised its option to obtain an exclusive license to develop and commercialize an Accurin drug candidate for the treatment of solid tumors under the companies' global collaboration agreement. The actively targeted Accurin is designed to impart cellular targeting capability and was engineered by BIND using one of Pfizer's proprietary kinase inhibitors and one of BIND's proprietary ligands. As a result of the option exercise, BIND will receive a $2.5 million option exercise fee from Pfizer. In parallel with exercising its first option, Pfizer informed BIND that it will not exercise its option for the second compound in the collaboration. Under terms of the original collaboration agreement, which was established in April 2013, Pfizer was granted options to obtain exclusive licenses to pursue development and commercialization of two Accurins that incorporate specified Pfizer small molecular targeted therapies. For the Accurin that has been selected, both companies will work together on preclinical research; Pfizer will have responsibility for development and commercialization, and BIND will conduct chemistry, manufacturing and control activities. In addition to the $2.5 million option exercise fee, BIND received an upfront payment of $4.0 million in 2013 and achieved a $1.0 million preclinical development milestone for the selected Accurin in December 2014. BIND has the potential to receive additional milestone payments for the selected Accurin of up to $86.0 million in aggregate upon the achievement of additional specified development and regulatory events under the Pfizer collaboration agreement. BIND may also receive additional milestone payments for the selected Accurin of up to $110 million in aggregate for specified commercial events as well as royalties in the low single to high single digit percentages on potential future sales of the selected Accurin, if any.
September 23, 2015
08:50 EDTMRKProvectus initiates Phase 1b/2 trial of PV-10 combo with Pembrolizumab
Provectus Biopharmaceuticals (PVCT) announced it has completed development of the protocol for Phase1b/2 testing of its investigational cancer drug PV-10 in combination with pembrolizumab in patients with Stage IV melanoma. Pembrolizumab, also known as Keytruda, a product of Merck (MRK), is an immune checkpoint inhibitor approved for treatment of patients with advanced or unresectable melanoma. PV-10 is Provectus's novel investigational drug for cancer that is injected into solid tumors. It is currently undergoing Phase 3 clinical testing in patients with Stage III melanoma. Clinical testing under the new Phase 1b/2 protocol is expected to commence before the end of the year. The FDA granted accelerated approval to pembrolizumab in September 2014, making it the first FDA-approved anti-PD-1 immune checkpoint inhibitor. Because pembrolizumab is already FDA-approved, Provectus can commence this study with or without assistance of a partner.
05:32 EDTPFEViiV Healthcare announces Triumeq Phase IIIb study met primary endpoint
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use